AGM/EGMAug 3, 2026, 04:13 PM
Soligenix Proposes Reverse Stock Split, Increases Authorized Shares
AI Summary
Soligenix, Inc. filed its definitive proxy statement for its Annual Meeting of Stockholders on September 17, 2026. Key proposals include a reverse stock split (1-for-2 to 1-for-20) and an increase in authorized common stock from 75 million to 125 million, both aimed at maintaining the Nasdaq listing and providing strategic flexibility. The company also provided updates on its pipeline, noting the discontinuation of the Phase 3 HyBryte™ study but promising Phase 2 results for SGX945 and progress with its ThermoVax® platform.
Key Highlights
- Annual Meeting of Stockholders scheduled for September 17, 2026, virtually.
- Proposes a reverse stock split at a ratio of 1-for-2 to 1-for-20 to maintain Nasdaq listing.
- Seeks to increase authorized common stock from 75,000,000 to 125,000,000 shares.
- Board recommends voting "FOR" both the reverse stock split and authorized share increase proposals.
- Phase 3 FLASH2 study for HyBryte™ (CTCL) was discontinued following interim analysis.
- SGX945 (dusquetide) showed promising preliminary efficacy in Phase 2 for Behçet’s disease.
- Advancing heat-stable Bundibugyo Ebola vaccine program using ThermoVax® platform.
- Actively exploring strategic alternatives, including partnerships, licensing, and M&A.
Price Impact
More from SNGX